acid ceramidase

Acid Ceramidase-IN-1 is a highly effective, orally bioavailable inhibitor of acid ceramidase (AC, ASAH-1) with an IC50 of 0.166 μM and exhibits exceptional brain penetration capabilities in mice.

LCL521 inhibits lysosomal acid sphingomyelinase (ASMase).LCL521 is an acid ceramidase (ACDase) inhibitor.

ARN14974 is a benzoxazolone carboxamide. ARN14974 is a potent inhibitor of acid ceramidase with IC50 of 79 nM[1].

Acid Ceramidase-IN-2 (compound 1), an acid ceramidase inhibitor, exhibits potentially antiproliferative and cytostatic effects. It is of interest due to the overexpression of human acid ceramidase in prostate cancer cells, suggesting potential anti-tumor efficacy. The hydrolysis of Acid Ceramidase-IN-2 can be inhibited by 3 a-ketoamides: GT85, GT98, and GT99 in vitro [1].

LCL521 dihydrochloride is a dual inhibitor of acid ceramidase (ACDase) and lysosomal acid sphingomyelinase (ASMase). By targeting these lysosomal enzymes, LCL521 dihydrochloride modulates sphingolipid metabolism, with potential applications in cancer and metabolic disorder research.

Carmofur (HCFU) is a highly potent acid ceramidase inhibitor, used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.

D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor and ceramide analog with potential antiproliferative activity that modulates ceramide signaling in human melanoma cells. D-NMAPPD is used in the study of colon cancer.

ARN14988 is a potent inhibitor of acid ceramidase (IC50 = 12.8 nM for the human enzyme). It inhibits acid ceramidase activity and increases levels of C16 dihydro ceramide and C16 ceramide in A375, G361, M14, MeWo, MNT-1, and SK-MEL-28 melanoma cells. ARN14988 also reduces growth of A375 and G361 melanoma cells (EC50s = 41.8 and 67.7 μM, respectively).

SABRAC inhibits acid ceramidase in PC3 MC metastatic prostate cancer cells (IC50 = <1 µM), as well as induces accumulation of ceramides in the same cells.

SOCLAC, a derivative of the acid ceramidase inhibitor SABRAC, functions as an irreversible inhibitor of acid ceramidase with an inhibition constant (Ki) of 40.2 nM.

SOBRAC, a derivative of the acid ceramidase inhibitor SABRAC, acts as an irreversible inhibitor of acid ceramidase (Ki= 29.7 nM).

W000113414_I13 serves as an acid ceramidase (AC) inhibitor, demonstrating dose-dependent inhibition with an IC50 of 6.6 μM. It is applicable for cancer research [1].